Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Beam Therapeutics, Inc. (BEAM)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$25.87-6.91%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for BEAM yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Advance and expand base editing product pipeline | Beam is advancing its gene editing portfolio with strong trial data. | Intact | Failure to report meaningful progress or trial setbacks by end 2026 | Qualitative progress: BEAM-302 Phase 1/2 data updated (Sep 2026) and AATD trial data presented (May 2026) Updated Phase 1/2 data for BEAM-302 and positive AATD trial results support continued base editing portfolio expansion. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
BEAM is a speculative, clinical-stage biotechnology business, not an established earnings compounder. Its thesis state is watch: programs are advancing, but recent financial performance is weak and the business is loss-making.
BEAM carries a durable premium versus peers, and the evidence labels that premium unjustified. The expectations gap is 0.8, with medium model confidence, but the snapshot does not say exactly which future outcomes market expectations assume.
Over the near term, earnings risk is elevated after the latest quarter missed and recent surprises have been erratic. Management has made progress on BEAM-302, risto-cel, and BEAM-304, but each priority is rated mixed, so clinical and regulatory execution remains important. The Healthcare sector backdrop has strengthened, though weaker employment could raise recession concerns across the sector.
The multi-year thesis depends on continued clinical progress, including the planned risto-cel regulatory submission by year-end 2026 and further BEAM-302 and BEAM-304 milestones. A guidance cut or another weak earnings result would add to near-term concerns. Strong results and guidance from Healthcare bellwethers could support sector momentum, while weakening employment could weigh on the sector.
For the next 1 to 3 years, BEAM remains a high-risk clinical progress story with an unjustified premium, weak recent results, and meaningful milestones ahead. The long-term thesis hinges on execution and clinical progress, while near-term earnings and sector conditions remain risks. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Manage operating losses |
| Operating losses are being managed with some progress. |
| Under Pressure |
| Operating losses worsen beyond -$110M per quarter over next 4 quarters |
Operating income: $-141.322M FY2026-Q3; GAAP. Published target: Operating loss no worse than -$107M in Q1 2026 and improving thereafter. Target period is not explicitly aligned with this observation. Nov 3, 2026-141,322,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Limit revenue decline | A supporting condition in Beam Therapeutics, Inc.'s published investment case. The stated target is Revenue decline less than -35% in 2026. | Intact | Revenue decline exceeds -40% in 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Secure financing to cover expenses into 2029 | It aims to secure financing through 2029. | Intact | Failure to secure or maintain financing covering expenses beyond 2027 | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-4.73 → $-4.94 · observed estimates
$0.10B → $0.05B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-4.73 | $96,069,740 | 11 / 12 |
| 2026-07-25 | $-4.73 | $96,069,740 | 11 / 12 |
| 2026-07-26 | $-4.73 | $96,069,740 | 11 / 12 |
| 2026-07-27 | $-4.73 | $96,069,740 | 11 / 12 |
| 2026-07-28 | $-4.73 | $96,069,740 | 11 / 12 |
| 2026-07-29 | $-4.73 | $96,069,740 | 11 / 12 |
| 2026-07-30 | $-4.73 | $96,069,740 | 11 / 12 |
| 2026-07-31 | $-4.55 | $92,118,085 | 9 / 9 |
| 2026-08-01 | $-4.73 | $96,069,740 | 11 / 12 |
| 2026-08-02 | $-4.73 | $96,069,740 | 11 / 12 |
| 2026-08-03 | $-4.73 | $96,069,740 | 11 / 12 |
| 2026-08-04 | $-4.73 | $96,069,740 | 11 / 12 |
| 2026-08-05 | $-4.73 | $96,069,740 | 11 / 12 |
| 2026-08-06 | $-4.71 | $91,793,690 | 12 / 10 |
| 2026-08-07 | $-4.66 | $64,334,669 | 9 / 8 |
| 2026-08-08 | $-4.71 | $91,793,690 | 12 / 10 |
| 2026-08-09 | $-4.63 | $73,089,580 | 13 / 11 |
| 2026-08-10 | $-4.63 | $73,089,580 | 13 / 11 |
| 2026-08-11 | $-4.74 | $62,748,780 | 12 / 12 |
| 2026-08-12 | $-4.74 | $62,748,780 | 12 / 12 |
| 2026-08-13 | $-4.74 | $62,748,780 | 12 / 12 |
| 2026-08-14 | $-4.66 | $64,334,669 | 9 / 8 |
| 2026-08-15 | $-4.66 | $64,334,669 | 9 / 8 |
| 2026-08-16 | $-4.66 | $64,334,669 | 9 / 8 |
| 2026-08-17 | $-4.66 | $64,334,669 | 9 / 8 |
| 2026-08-18 | $-4.66 | $64,334,669 | 9 / 8 |
| 2026-08-19 | $-4.66 | $64,334,669 | 9 / 8 |
| 2026-08-20 | $-4.74 | $56,048,954 | 9 / 9 |
| 2026-08-21 | $-4.74 | $56,048,954 | 9 / 9 |
| 2026-08-22 | $-4.74 | $56,048,954 | 9 / 9 |
| 2026-08-23 | $-4.74 | $56,048,954 | 9 / 9 |
| 2026-08-24 | $-4.74 | $56,048,954 | 9 / 9 |
| 2026-08-25 | $-4.74 | $56,048,954 | 9 / 9 |
| 2026-08-26 | $-4.74 | $56,048,954 | 9 / 9 |
| 2026-08-27 | $-4.74 | $56,048,954 | 9 / 9 |
| 2026-08-28 | $-4.74 | $56,048,954 | 9 / 9 |
| 2026-08-29 | $-4.74 | $56,048,954 | 9 / 9 |
| 2026-08-30 | $-4.74 | $56,048,954 | 9 / 9 |
| 2026-08-31 | $-4.74 | $56,048,954 | 9 / 9 |
| 2026-09-01 | $-4.74 | $56,048,954 | 9 / 9 |
| 2026-09-02 | $-4.74 | $56,048,954 | 9 / 9 |
| 2026-09-03 | $-4.79 | $56,048,954 | 9 / 9 |
| 2026-09-04 | $-4.79 | $56,048,954 | 9 / 9 |
| 2026-09-05 | $-4.79 | $56,048,954 | 9 / 9 |
| 2026-09-06 | $-4.79 | $56,048,954 | 9 / 9 |
| 2026-09-07 | $-4.79 | $56,048,954 | 9 / 9 |
| 2026-09-08 | $-4.79 | $56,048,954 | 9 / 9 |
| 2026-09-09 | $-4.79 | $56,070,390 | 9 / 9 |
| 2026-09-10 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-09-11 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-09-12 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-09-13 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-09-14 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-09-15 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-09-16 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-09-17 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-09-18 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-09-19 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-09-20 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-09-21 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-09-22 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-09-23 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-09-24 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-09-25 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-09-26 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-09-27 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-09-28 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-09-29 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-09-30 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-10-01 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-10-02 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-10-03 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-10-04 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-10-05 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-10-06 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-10-07 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-10-08 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-10-09 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-10-10 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-10-11 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-10-12 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-10-13 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-10-14 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-10-15 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-10-16 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-10-17 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-10-18 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-10-19 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-10-20 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-10-21 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-10-22 | $-4.79 | $63,834,676 | 9 / 9 |
| 2026-10-23 | $-4.81 | $63,834,676 | 10 / 9 |
| 2026-10-24 | $-4.81 | $63,834,676 | 10 / 9 |
| 2026-10-25 | $-4.81 | $63,834,676 | 10 / 9 |
| 2026-10-26 | $-4.81 | $63,834,676 | 10 / 9 |
| 2026-10-27 | $-4.81 | $63,834,676 | 10 / 9 |
| 2026-10-28 | $-4.82 | $62,266,530 | 10 / 9 |
| 2026-10-29 | $-4.82 | $62,266,530 | 10 / 9 |
| 2026-10-30 | $-4.82 | $62,266,530 | 10 / 9 |
| 2026-10-31 | $-4.82 | $62,266,530 | 10 / 9 |
| 2026-11-01 | $-4.82 | $62,266,530 | 10 / 9 |
| 2026-11-02 | $-4.82 | $62,266,530 | 10 / 9 |
| 2026-11-03 | $-4.82 | $62,266,530 | 10 / 9 |
| 2026-11-04 | $-4.94 | $49,149,028 | 11 / 8 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 13 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 5 recorded
0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.